Status:
UNKNOWN
Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children
Lead Sponsor:
Zagazig University
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
6-12 years
Phase:
PHASE3
Brief Summary
Better management and improving outcome of children with allergic rhinitis
Detailed Description
The prevelance of Allergic Respiratory Diseases has been increased worldwide and affect 1of 5 persons of general population . ARDs are triggered by exposure to allergen and includes allergic rhinitis ...
Eligibility Criteria
Inclusion
- 1\. Children with moderate to severe allergic rhinitis according to Allergic Rhinitis And Its Impact On Asthma (ARIA) guidelines\[9\], which interfere with daily activity or sleep.
- 2\. Children aged (6-12) years with clinical history of allergic rhinitis for at least one year.
- 3\. Children with allergic rhinitis who failed medical treatment, desire an alternative to pharmacotherapy.
- 4\. Sex : male and female.
Exclusion
- \- 1. Children with chronic lung \& heart diseases as: asthma and anatomical malformation for respiratory system.
- 2\. disorders: Gastro Esophageal Reflux Disease, cystic fibrosis and epilepsy. 3.Children with chronic drug use: oral or nasal corticosteroids, antiepileptic and immunosuppressive.
Key Trial Info
Start Date :
April 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 20 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04851860
Start Date
April 12 2021
End Date
November 20 2021
Last Update
April 21 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.